NCT01384747View on ClinicalTrials.gov

Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)

PHASE4TerminatedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Coronary Artery Disease
Interventions
DRUG

Fimasartan

60-120mg/day (target dose) of Fimasartan will be administered for the study period (till the follow-up angiography)

DRUG

Placebo

60-120mg/day (target dose) of Placebo will be administered for the study period (till the follow-up angiography)

Trial Locations (3)

501-757

Chonnam National University Hospital, Gwangju

138-736

Asan Medical Center, Seoul

682-714

Ulsan University Hospital, Ulsan

Sponsors
All Listed Sponsors
collaborator

CardioVascular Research Foundation, Korea

OTHER

collaborator

Boryung Pharmaceutical Co., Ltd

INDUSTRY

lead

Seung-Jung Park

OTHER